U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O.Zn
Molecular Weight 81.408
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Zinc oxide

SMILES

[O--].[Zn++]

InChI

InChIKey=RNWHGQJWIACOKP-UHFFFAOYSA-N
InChI=1S/O.Zn/q-2;+2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Erythrocyte zinc content in critically ill patients.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:38:40 GMT 2023
Edited
by admin
on Fri Dec 15 15:38:40 GMT 2023
Record UNII
SOI2LOH54Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Zinc oxide
EP   FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
Zinc oxide [WHO-DD]
Common Name English
ZINC OXIDE COMPONENT OF VUSION
Common Name English
C.I. 77947
Common Name English
ZINC OXIDE [USP-RS]
Common Name English
ZINC WHITE
Common Name English
ZINC (AS ZINC OXIDE) [VANDF]
Common Name English
ZINC OXIDE COMPONENT OF CALAMINE
Common Name English
CALAMINE COMPONENT ZINC OXIDE
Common Name English
CI 77947
INCI  
INCI  
Official Name English
C.I. PIGMENT WHITE 4
Common Name English
ZINCUM OXYDATUM
HPUS  
Common Name English
ZINC OXIDE NEUTRAL [USP MONOGRAPH]
Common Name English
ZINC OXIDE [MART.]
Common Name English
ZINC OXIDE EMULSION [VANDF]
Common Name English
ZINC OXIDE [WHO-IP]
Common Name English
ZINC PASTE [VANDF]
Common Name English
ZINC OXIDE [HSDB]
Common Name English
ZINC OXIDE [INCI]
Common Name English
ZINC OXIDE [ORANGE BOOK]
Common Name English
ZINC OXIDE [FCC]
Common Name English
ZINC OXIDE [USP IMPURITY]
Common Name English
ZINC OXIDE [EP MONOGRAPH]
Common Name English
ZINC OXIDE [II]
Common Name English
ZINCI OXYDUM [WHO-IP LATIN]
Common Name English
ZINC OXIDE [JAN]
Common Name English
ZINC OXIDE [VANDF]
Common Name English
CI 77947 [INCI]
Common Name English
ZINC (AS OXIDE) [VANDF]
Common Name English
VUSION COMPONENT ZINC OXIDE
Common Name English
ZINC PASTE
VANDF  
Common Name English
ZINC OXIDE [MI]
Common Name English
ZINCUM OXYDATUM [HPUS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 178.3297
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 175.300
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 175.380
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 177.1460
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 177.1900
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
FDA ORPHAN DRUG 142401
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 310.531
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 352.20
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 352.10
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
WHO-VATC QA07XA91
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
Food Contact Sustance Notif, (FCN No.) FCN NO. 193
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
EPA PESTICIDE CODE 88502
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 347.10
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
NCI_THESAURUS C851
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 346.18
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 177.1350
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
CFR 21 CFR 176.170
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
Code System Code Type Description
DRUG BANK
DB09321
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
MERCK INDEX
m11617
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1724747
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
SMS_ID
100000089333
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
PUBCHEM
3007857
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
WIKIPEDIA
ZINC OXIDE
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ZINC OXIDE
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY Description: A white or faintly yellowish white, very fine, amorphous powder, free from grittiness; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS. Category: Mild astringent used topically as a protective. Storage: Zinc oxide should be kept in a well-closed container. Additional information: Zinc oxide gradually absorbs carbon dioxide from the air. Definition: Zinc oxide contains not less than 99.0% and not more than 100.5% of ZnO, calculated with reference to the freshly ignited substance.
EVMPD
SUB12623MIG
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID7035016
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
MESH
D015034
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
DRUG CENTRAL
4240
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
NCI_THESAURUS
C949
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
HSDB
5024
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
RXCUI
11423
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY RxNorm
CAS
1314-13-2
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
CHEBI
36560
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201128
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
FDA UNII
SOI2LOH54Z
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
DAILYMED
SOI2LOH54Z
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-222-5
Created by admin on Fri Dec 15 15:38:40 GMT 2023 , Edited by admin on Fri Dec 15 15:38:40 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY